Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

nt; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

FAVRILLE, INC.

(a development stage company)

BALANCE SHEETS

(in thousands, except share and per share data)

December 31,

2007 2006

(unaudited)

Assets

Current assets:

Cash and cash equivalents $26,362 $14,249

Short-term investments 3,577 28,160

Other current assets 806 850

Total current assets 30,745 43,259

Property and equipment, net 33,293 25,071

Restricted cash 3,451 3,451

Other assets 466 508

Total assets $67,955 $72,289

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued liabilities $3,551 $6,779

Current
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... STOCKHOLM , Aug. 31, 2015 Trimb ... an agreement to acquire YouMedical Group BV ("YouMedical"), a ... YouMedical has total annual sales of approximately EUR 16 ... categories. "Our ambition is to build ... an important step toward that goal. YouMedical gives us ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... There’s a ... Minerva is the first commercially available new FDA approved system in the last ... rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Global & USA BioSimilar Market Analysis ... The highly awaited US Biosimilar market will be initiated ... biologic, Zarxio. How will the global market react? Will ... that biosimilars could save the US economy up to ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... (OMeGA) has chosen its 2009 grant recipients. OMeGA ... medical education to which Zimmer committed $2 million in ... , OMeGA received more than 250 applications for its ...
... Corporation (NYSE: SYK ) learned today that a federal ... indictment charging Stryker Biotech LLC and certain current and former ... the U.S. Food and Drug Administration (FDA), distribution of a ... disclosed in March of this year that its Biotech division ...
... , INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, ... it has priced a $300 million securitization transaction intended ... royalties. , Upon closing of the transaction, which is ... will sell to QHP Royalty Sub LLC ("QHP"), a ...
Cached Biology Technology:Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 2Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 3Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients 4Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... , 31 de julio de 2015 La ... ) se celebrará por medio de BGI del 22 al 25 ... . Este año, la conferencia celebra su ... se ha convertido en una de las reuniones anuales más ... una de las reuniones más dinámicas, entusiastas y mejores a ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... of who will carry the burden but could instead ... economic modeling presented today at "Climate Change: Global Risks, ... Contrary to current cost models for lowering ... of researchers from the University of Cambridge conclude that ...
... condition that affects millions of people, but two ... the genes that are causing problems. Michele ... Rehabilitation Medicine, have discovered eight genes that are ... more genes associated with disc degeneration than was ...
... NY) ─ For the third time in 14 months, ... Einstein College of Medicine of Yeshiva University funding for ... will help create technologies for treating sickle cell anemia, ... and hepatitis. In applauding President Obama,s executive order ...
Cached Biology News:Fighting global warming offers growth and development opportunities 2Fighting global warming offers growth and development opportunities 3Genes identified that are linked to spinal disc degeneration 2Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine 2Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine 3
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da...
Biology Products: